

Advancing the Development of Live Biotherapeutic Products to Combat Infections

Scientific Program

Wednesday, 2nd of April, 2025

Arrival and Check-in	
Lunch	12:00 - 13:00
Welcome and opening remarks Prof. Andreas Peschel / Eberhard Karls University Tuebingen Prof. Till Strowig / Helmholtz Centre for Infection Research, Brunswick Prof. Maria Vehreschild / University Clinic Cologne & Frankfurt	13:00 - 13:15
Session 1: Preclinical Identification of LBP Candidates	
Gut decolonization of multidrug-resistant <i>Escherichia coli</i> clinical isolates via cooperative niche exclusion Dr. Marie Wende / Helmholtz Centre for Infection Research, Brunswick	13:15 - 13:40
Public goods shape <i>S. aureus</i> proliferation within nasal communities Prof. Simon Heilbronner / Ludwig-Maximilians University, Munich	13:40 -14:05
Enabling the next generation of biotherapeutics by determining the taxonomic and functional diversity of bacteria in the human gut. Prof. Thomas Clavel / University Hospital of RWTH Aachen	14:05 -14:30
Patenting and technology transfer Dr. J. Krauß / SKP-IP, Munich	14:30 -15:00
Coffee Break	15:00 - 15:30
Session 2: Developing Preclinical LBP Candidates into drugs - Success Stories and Key Technologies	
Keynote lecture: Next-generation probiotics: from conceptual development to commercial product Prof. Muhammad Tanweer Khan / Göteborg, Sweden	15:30 -16:15
Living Therapeutic Materials: Hydrogel-encapsulated bacteria for smart drug delivery Dr. Shrikrishnan Sankaran / INM - Leibniz Institute for New Materials, Saarbrücken	16:15 -16:40
Keynote lecture: Controlled human colonization and infection by <i>Clostridioides difficile</i> to gain insight into disease and accelerate drug development Prof. Wiep Klaas Smits / Leiden, Netherlands	16:40 -17:25
An in vitro gut community model for the evaluation of decolonizing strategies and microbiome interventions Dr. Thomas Fließwasser / University Hospital Bonn	17:25 -17:50
Conclusions of day 1	17:50 -18:00
Dinner and Scientific Networking	18:00 -19:00
Poster Session	19:30

Thursday, 3rd of April, 2025

Session 3: Production and Quality Control of LBP – Real-World Experiences	
Understanding regulatory differences and manufacturing requirements between FMT and LBP Prof. Maria Vehreschild /University Clinic Cologne & Frankfurt	09:00 - 09:30
Commercial LBP production – a developing landscape Dr. Lisa Osbelt-Block / Helmholtz Centre for Infection Research, Brunswick	09:30 - 10:00
The challenges of clinical trials with live biotherapeutic products on the basis of the phase I clinical trial LuCa UKT01 – Nasal application of <i>S. lugdunensis</i> Meral Esen & Marcel Spring /University Clinic Tuebingen	10:00 -10:30
Coffee Break	10:30 -11:00
Session 4: The Regulatory Landscape of LBP Development	
Panel discussion with representatives from BfArM, PEI and DZIF including TI PDU Dr. Nils Lilienthal and colleagues / BfArM, Bonn Dr. Oleg Knut, Dr. Holger Lößner and colleagues / PEI, Langen Dr. Thomas Hesterkamp and colleagues / DZIF Product Development Unit, Brunswick	11:00 -12:30
Lunch /Box lunch	12:30 -13:15
Departure	

Location

CJD Bonn Castell
Graurheindorfer Str. 149,
53117 Bonn
Germany



Organizers: Till Strowig & Lisa Maier on behalf of the members of the DZIF BT Microbiome

Questions? → agnieszka-elzbieta.mitulski@uni-tuebingen.de